Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01271244 · ClinicalTrials.gov registry record · Phase 4

Effects of Escitalopram on Autonomic Reactivity in Post Traumatic Stress Disorder

A Phase 4 study of PTSD, sponsored by VA Nebraska Western Iowa Health Care System.

Completed
Registry status
Phase 4
Development phase
26
Enrollment target
1
Study location

NCT01271244: Completed Phase 4 study of PTSD, sponsored by VA Nebraska Western Iowa Health Care System.

NCT01271244 is a Phase 4 study of PTSD that has completed, run by VA Nebraska Western Iowa Health Care System. The registered enrollment target is 26 participants, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01271244, a Phase 4 study of PTSD, has completed, sponsored by VA Nebraska Western Iowa Health Care System.

COMPLETED
Registry status
Phase 4
Development phase
26 participants
Enrollment target
1
Study location

Study Summary

The study looked at relationship between escitalopram and heart rate variability and QT variability in veterans with PTSD.

Primary Outcome

Heart rate variability is the standard deviation of successive R-to-R intervals, or variability in time between successive heart beats. Spectral power in the high frequency (HF: 0.15-0.5 Hz) band reflects parasympathetic input, or cardiac vagal function. A natural log (ln) transformation was applied to heart rate variability data to derive the outcome measure.

Conditions Studied

Interventions

  • DRUG Escitalopram

Study Locations (1)

Nebraska

  • Omaha Veterans Affairs Medical Center - Omaha

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2008-06
Est. Completion 2013-06
Phase Phase 4

What the finished NCT01271244 record still lists

NCT01271244 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (91% lower).

The record links to 1 condition, with PTSD appearing as the primary indexed condition, and to 1 intervention - of which Escitalopram is the first listed.

NCT01271244 reports a single indexed study location in Nebraska.

Frequently Asked Questions

What is clinical trial NCT01271244 about?

NCT01271244 is a clinical study titled "Effects of Escitalopram on Autonomic Reactivity in Post Traumatic Stress Disorder". The study looked at relationship between escitalopram and heart rate variability and QT variability in veterans with PTSD.

What is the current status of trial NCT01271244?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2008-06. Estimated completion is 2013-06.

What conditions does trial NCT01271244 study?

This clinical trial studies the following conditions: PTSD.

What interventions are being tested in trial NCT01271244?

The interventions under investigation include: Escitalopram (DRUG).

Who is sponsoring clinical trial NCT01271244?

This trial is sponsored by VA Nebraska Western Iowa Health Care System, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01271244 being conducted?

This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for PTSD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01271244's enrollment target sits among peer trials

26 132nd of 154 higher than 22 of 154 other PTSD trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other PTSD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02646475 · 26 participants · Phase 1

    Metabolic Effects of Angiotensin-(1-7)

  • NCT03603223 · 26 participants · Phase 2

    Pembrolizumab in Treating Participants With Leukoplakia

  • NCT04063592 · 26 participants · NA

    AMI Construction in Lower Extremity Residual Limbs

  • NCT04906460 · 26 participants · Phase 1

    Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01271244, the US trial registry maintained by the National Library of Medicine. NCT01271244 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.